ReviewRSC advances2023
Success stories of natural product-derived compounds from plants as multidrug resistance modulators in microorganisms.
Review in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Plant Volatile Nanoemulsion Resensitize Pseudomonas aeruginosa to Benzalkonium Chloride.Current microbiology · 2026Article
- Phytochemical Elucidation and Biological Activity Spectrum ofMetabolites · 2026Article
- Targeting histidine biosynthesis in Acinetobacter baumannii: structure-based discovery of natural inhibitors of ATP-phosphoribosyltransferase.Molecular diversity · 2026Article
- Invasive Giant Goldenrod (Molecules (Basel, Switzerland) · 2026Article
- Investigation of antimicrobial and antivirulence effects of lactobionic acid and carvacrol, individually and in combination, against Escherichia coli isolates.Molecular biology reports · 2026Article
- Mechanisms of Bacterial Resistance and Innovative Strategies to Overcome Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2026Review
- Co-development of efflux pump inhibitors with antibiotics on targeting structural and mutational aspects of AcrB subunit.Molecular diversity · 2026Article
- Article
- Polyphenolic compounds inFrontiers in pharmacology · 2026Review
- Bacterial secondary metabolites as resistance-modifying adjuvants: microbial origins, molecular mechanisms, and translational relevance.Frontiers in microbiology · 2026Review
- Review
- The antibacterial activity, action mechanisms and prospects of Baicalein as an antibacterial adjuvant.World journal of microbiology & biotechnology · 2025Review
- Antibacterial Activity of PeruvianInternational journal of microbiology · 2025Article
- Metabolic Comparison and Molecular Networking of Antimicrobials inInternational journal of molecular sciences · 2024Article
- Potential of Flavonoids as Promising Phytotherapeutic Agents to Combat Multidrug-Resistant Infections.Current pharmaceutical biotechnology · 2024Review
- In Vitro Synergistic Inhibitory Effects of Plant Extract Combinations on Bacterial Growth of Methicillin-ResistantPharmaceuticals (Basel, Switzerland) · 2023Article
- Antibacterial and Antimycotic Activity ofPharmaceuticals (Basel, Switzerland) · 2023Review
- Antibacterial and antiviral properties of punicalagin (Review).Medicine internationalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microorganisms evolve resistance to antibiotics as a function of evolution. Antibiotics have accelerated bacterial resistance through mutations and acquired resistance through a combination of factors. In some cases, multiple antibiotic-resistant determinants are encoded in these genes, immediately making the recipient organism a "superbug". Current antimicrobials are no longer effective against infections caused by pathogens that have developed antimicrobial resistance (AMR), and the problem has become a crisis. Microorganisms that acquire resistance to chemotherapy (multidrug resistance) are a major obstacle for successful treatments. Pharmaceutical industries should be highly interested in natural product-derived compounds, as they offer new sources of chemical entities for the development of new drugs. Phytochemical research and recent experimental advances are discussed in this review in relation to the antimicrobial efficacy of selected natural product-derived compounds as well as details of synergistic mechanisms and structures. The present review recognizesand amplifies the importance of compounds with natural origins, which can be used to create safer and more effective antimicrobial drugs by combating microorganisms that are resistant to multiple types of drugs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.